|
1
|
Yang XR, Sun HC, Xie Q, Zhang WG, Jia WD, Zhao M, Zhao HT, Liu XF, Zhou LD, Yan S, Xu L, Wang NY, Ding Y, Zhu XD, Zhou J, Fan J. [Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma]. Zhonghua Gan Zang Bing Za Zhi 2023; 31:1018-1029. [PMID: 38016765 DOI: 10.3760/cma.j.cn115610-20230201-00035-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/30/2023]
Abstract
Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4, 2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.
Collapse
Affiliation(s)
- X R Yang
- Department of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - H C Sun
- Department of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Q Xie
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
| | - W G Zhang
- Hepatic Surgery Center,Tongji Hospital,Tonji Medical College, Huazhong University of Science and Technolog, Wuhan 430030, China
| | - W D Jia
- Department of Liver Surgery, the First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China
| | - M Zhao
- Department of Minimally Invasive and Interventional, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China
| | - H T Zhao
- Department of Hepatic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
| | - X F Liu
- Department of Oncology, Qinhuai Medical District, Eastern Theater General Hospital of PLA, Nanjing 210002, China
| | - L D Zhou
- Department of Liver Surgery, Xiangya Hospital of Central South University, Changsha 410008, China
| | - S Yan
- Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China
| | - L Xu
- Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - N Y Wang
- Department of Cancer Center, the First Hospital of Jilin University, Changchun 130021, China
| | - Y Ding
- Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China
| | - X D Zhu
- Department of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - J Zhou
- Department of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - J Fan
- Department of Liver Surgery, Research Institute of Liver Cancer, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| |
Collapse
|